Outcomes in higher-risk and lower-risk patients in the HRD-negative subgroup
| Higher risk | Lower risk | ||||
| Olaparib + bevacizumab (n=144) | Placebo + bevacizumab (n=62) | Olaparib + bevacizumab (n=48) | Placebo + bevacizumab (n=23) | ||
| PFS* | |||||
| Events, n (%) | 130 (90) | 57 (92) | 37 (77) | 17 (74) | |
| Median PFS, months | 15.2 | 13.8 | 23.8 | 22.9 | |
| HR (95% CI) | 0.92 (0.68 to 1.27) | 1.12 (0.64 to 2.03)† | |||
| 5-year PFS rate,‡ % | 6 | 7 | 15 | 26 | |
| TFST* | |||||
| Events, n (%) | 135 (94) | 55 (89) | 37 (77) | 19 (83) | |
| Median TFST, months | 16.5 | 14.1 | 27.3 | 26.3 | |
| HR (95% CI) | 0.97 (0.71 to 1.34) | 1.00 (0.58 to 1.77)† | |||
| 5-year TFST rate,‡ % | 5 | 10 | 20 | 18 | |
| OS | |||||
| Events, n (%) | 116 (81) | 46 (74) | 24 (50) | 12 (52) | |
| Median OS, months | 31.6 | 28.5 | 59.3 | 56.2 | |
| HR (95% CI) | 1.15 (0.82 to 1.63) | 1.14 (0.58 to 2.38) | |||
| 5-year OS rate,‡ % | 18 | 26 | 48 | 49 | |
| Patients receiving a PARP inhibitor during any subsequent treatment, n (%) | 32 (22) | 21 (34) | 14 (29) | 13 (57) | |
HRD-negative defined as GIS < 42 and no tumor BRCA mutation (MyChoice HRD Plus).
*5-year PFS and TFST data from the final overall survival data cut-off (March 22, 2022).
†Survival curves cross; interpret HRs with caution.
‡Kaplan-Meier estimates.
BRCAm, BRCA1 and/or BRCA2 mutation; GIS, genomic instability score; HRD, homologous recombination deficiency; OS, overall survival; PARP, poly(ADP-ribose) polymerase; PFS, progression-free survival; TFST, time to first subsequent therapy or death.